- TIVDAK caused changes in the corneal epithelium and conjunctiva resulting in changes in vision, including severe vision loss, and corneal ulceration.
- Conduct an ophthalmic exam at baseline, prior to each dose, and as clinically indicated.
- Adhere to premedication and required eye care before, during, and after infusion.
- Withhold TIVDAK until improvement and resume, reduce the dose, or permanently discontinue, based on severity.
Patient Counseling Information
Updated October 2021